|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/445 | (2006.01) |
| A61P 3/00 | (2006.01) |
| (11) | Number of the document | 3840753 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19703514.0 |
| Date of filing the European patent application | 2019-01-16 | |
| (97) | Date of publication of the European application | 2021-06-30 |
| (45) | Date of publication and mention of the grant of the patent | 2024-07-24 |
| (46) | Date of publication of the claims translation | 2024-11-11 |
| (86) | Number | PCT/US2019/013761 |
| Date | 2019-01-16 |
| (87) | Number | WO 2020/040806 |
| Date | 2020-02-27 |
| (30) | Number | Date | Country code |
| 201862719962 P | 2018-08-20 | US |
| (72) |
BENJAMIN, Elfrida , US
|
| (73) |
Amicus Therapeutics, Inc. ,
3675 Market Street, Philadelphia, PA 19104,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Migalastatas skirtas naudoti Fabry ligos gydymo būdui, pacientams turintiems GLA geno mutaciją |
| MIGALASTAT FOR USE IN METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING A MUTATION IN THE GLA GENE |
| Payment date | Validity (years) | Amount | |
| 2025-12-04 | 8 | 185.00 EUR |
| 2027-01-16 |